InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by BERMAN ROBERT ANDREW. Director active across 2 companies, notably Hancock Jaffe Laboratories, Inc.. Aggregated, 9 disclosures have been logged. Total volume traded: €90k. The latest transaction was filed on 27 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations9 total
€8,9782,500 shares@ €3.59140.14% mcap14.3% of flow
Common Stock
SEC:0001493152-22-017957:0·
Ideal exit: 24 Mar 2023 (T+270)
200,000 shares
Common Stock
SEC:0001493152-21-030335·
200,000 shares
Common Stock
SEC:0001493152-21-030335:0·
€13,0712,000 shares@ €6.535748.6% of flow
Common Stock
SEC:0001493152-21-029430·
Ideal exit: 16 Aug 2022 (T+270)
€13,0712,000 shares@ €6.53570.20% mcap20.8% of flow
Common Stock
SEC:0001493152-21-029430:0·
Ideal exit: 16 Aug 2022 (T+270)
€13,8482,000 shares@ €6.923951.4% of flow
Common Stock
SEC:0001493152-21-029229·
Ideal exit: 13 Aug 2022 (T+270)
€13,8482,000 shares@ €6.92390.21% mcap22.0% of flow
Common Stock
SEC:0001493152-21-029229:0·
Ideal exit: 13 Aug 2022 (T+270)
€13,4243,000 shares@ €4.4748100.0% of flow
Common Stock, $0.00001 par value
SEC:0001493152-21-012298·
Ideal exit: 12 Feb 2022 (T+270)
€13,4243,000 shares@ €4.474850.0% of flow
Common Stock, $0.00001 par value
SEC:0001493152-21-012298:0·
Ideal exit: 12 Feb 2022 (T+270)
9 of 9 declarations
About BERMAN ROBERT ANDREW
Robert Andrew Berman is a director at Hancock Jaffe Laboratories, Inc. and enVVeno Medical Corp.
